menu
    • menu
    [{"orgOrder":0,"company":"University Hospital Center of Martinique","sponsor":"BioGaia Pharma | University Hospital, Limoges | Regional Health Agency, Martinique | Biological Resource Centre, Martinique | Reims University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Limosilactobacillus Reuteri","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Undisclosed","graph3":"University Hospital Center of Martinique","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"University Hospital Center of Martinique \/ BioGaia Pharma | University Hospital, Limoges | Regional Health Agency, Martinique | Biological Resource Centre, Martinique | Reims University Hospital","highestDevelopmentStatusID":"1","companyTruncated":"University Hospital Center of Martinique \/ BioGaia Pharma | University Hospital, Limoges | Regional Health Agency, Martinique | Biological Resource Centre, Martinique | Reims University Hospital"},{"orgOrder":0,"company":"Novozymes","sponsor":"Beijing Children's Hospital | Baoding Children's Hospital | Xuzhou Children Hospital | Chengdu Women's and Children's Central Hospital | Children's Hospital of Heibei Province | Beijing Clinical Service Center","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"DENMARK","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Lactobacillus Plantarum DSM 33464","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Undisclosed","graph3":"Novozymes","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Sachet","sponsorNew":"Novozymes \/ Beijing Children's Hospital | Baoding Children's Hospital | Xuzhou Children Hospital | Chengdu Women's and Children's Central Hospital | Children's Hospital of Heibei Province | Beijing Clinical Service Center","highestDevelopmentStatusID":"1","companyTruncated":"Novozymes \/ Beijing Children's Hospital | Baoding Children's Hospital | Xuzhou Children Hospital | Chengdu Women's and Children's Central Hospital | Children's Hospital of Heibei Province | Beijing Clinical Service Center"},{"orgOrder":0,"company":"Novozymes","sponsor":"Universidad Iberoamericana A.C., Mexico | Linus Biotechnology Inc","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"DENMARK","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Lactobacillus Plantarum DSM 33464","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Undisclosed","graph3":"Novozymes","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Sachet","sponsorNew":"Novozymes \/ Universidad Iberoamericana A.C., Mexico | Linus Biotechnology Inc","highestDevelopmentStatusID":"1","companyTruncated":"Novozymes \/ Universidad Iberoamericana A.C., Mexico | Linus Biotechnology Inc"},{"orgOrder":0,"company":"Anesthesia Research Group UA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Propofol","moa":"GABA-A receptor; anion channel","graph1":"Pharmacology\/Toxicology","graph2":"Undisclosed","graph3":"Anesthesia Research Group UA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anesthesia Research Group UA \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Anesthesia Research Group UA \/ Inapplicable"},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Mosedipimod","moa":"immunomodulators","graph1":"Pharmacology\/Toxicology","graph2":"Undisclosed","graph3":"Enzychem Lifesciences Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enzychem Lifesciences Corporation \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"Enzychem Lifesciences Corporation \/ National Institutes of Health"},{"orgOrder":0,"company":"Erdal","sponsor":"ActoPharma","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"GERMANY","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Undisclosed","graph3":"Erdal","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Erdal \/ ActoPharma","highestDevelopmentStatusID":"1","companyTruncated":"Erdal \/ ActoPharma"},{"orgOrder":0,"company":"Cultech Ltd","sponsor":"Comac Medical","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"LAB4","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Undisclosed","graph3":"Cultech Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cultech Ltd \/ Comac Medical","highestDevelopmentStatusID":"1","companyTruncated":"Cultech Ltd \/ Comac Medical"},{"orgOrder":0,"company":"Quantum BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"FSD-F2R6-A-CP","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Undisclosed","graph3":"Quantum BioPharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quantum BioPharma \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Quantum BioPharma \/ Inapplicable"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Quantum BioPharma

                            Canada arrow
                            CAMX
                            Not Confirmed

                            Quantum BioPharma

                            Canada arrow
                            CAMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FSD-F2R6-A-CP

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Assessing the Safety and Efficacy of FSD-F2R6-A-CP in Volunteers in an Induced State of Alcohol Intoxication

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 17, 2024

                            Lead Product(s) : FSD-F2R6-A-CP

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            University Hospital Center of Martinique

                            Country arrow
                            CAMX
                            Not Confirmed

                            University Hospital Center of Martinique

                            Country arrow
                            CAMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Limosilactobacillus Reuteri

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Undisclosed

                            Sponsor : BioGaia Pharma | University Hospital, Limoges | Regional Health Agency, Martinique | Biological Resource Centre, Martinique | Reims University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effects of Probiotic Oral Intake on Plasma Chlordecone (Kepone) Concentrations in Individuals Environmentally ...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            September 07, 2023

                            Lead Product(s) : Limosilactobacillus Reuteri

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Undisclosed

                            Sponsor : BioGaia Pharma | University Hospital, Limoges | Regional Health Agency, Martinique | Biological Resource Centre, Martinique | Reims University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Novozymes

                            Denmark arrow
                            CAMX
                            Not Confirmed

                            Novozymes

                            Denmark arrow
                            CAMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lactobacillus Plantarum DSM 33464

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Undisclosed

                            Sponsor : Universidad Iberoamericana A.C., Mexico | Linus Biotechnology Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Lactobacillus Plantarum DSM 33464 on Blood Lead Levels in Young Women of Child-bearing Age

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            August 18, 2022

                            Lead Product(s) : Lactobacillus Plantarum DSM 33464

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Undisclosed

                            Sponsor : Universidad Iberoamericana A.C., Mexico | Linus Biotechnology Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Anesthesia Research Group UA

                            Country arrow
                            CAMX
                            Not Confirmed

                            Anesthesia Research Group UA

                            Country arrow
                            CAMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Propofol

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vasopressor Requirements Depends on Sedation Strategy

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 11, 2022

                            Lead Product(s) : Propofol

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            CMC Pharmaceuticals

                            U.S.A arrow
                            CAMX
                            Not Confirmed

                            CMC Pharmaceuticals

                            U.S.A arrow
                            CAMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atropine Sulfate

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Undisclosed

                            Sponsor : US Department of Defense

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            CMC Pharmaceuticals Awarded SBIR Grant for Concentrated Atropine Formulation

                            Details : The Phase I SBIR award will fund the formulation and analytical development of a concentrated Atropine Sulfate Drug Product with the aim to aid the military in treating organophosphate poisoning in service members.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            June 04, 2022

                            Lead Product(s) : Atropine Sulfate

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Undisclosed

                            Sponsor : US Department of Defense

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Cultech Ltd

                            Country arrow
                            CAMX
                            Not Confirmed

                            Cultech Ltd

                            Country arrow
                            CAMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LAB4

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Undisclosed

                            Sponsor : Comac Medical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Impact of Probiotic Supplementation on Antibiotic Induced Changes in Gastrointestinal Function And/or Faec...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            May 02, 2022

                            Lead Product(s) : LAB4

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Undisclosed

                            Sponsor : Comac Medical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Novozymes

                            Denmark arrow
                            CAMX
                            Not Confirmed

                            Novozymes

                            Denmark arrow
                            CAMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lactobacillus Plantarum DSM 33464

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Undisclosed

                            Sponsor : Beijing Children's Hospital | Baoding Children's Hospital | Xuzhou Children Hospital | Chengdu Women's and Children's Central Hospital | Children's Hospital of Heibei Province | Beijing Clinical Service Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Trial to Evaluate the Efficacy and Safety of Lactobacillus Plantarum DSM 33464 on Blood Lead Levels in Child...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            May 18, 2021

                            Lead Product(s) : Lactobacillus Plantarum DSM 33464

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Undisclosed

                            Sponsor : Beijing Children's Hospital | Baoding Children's Hospital | Xuzhou Children Hospital | Chengdu Women's and Children's Central Hospital | Children's Hospital of Heibei Province | Beijing Clinical Service Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Enzychem Lifesciences Corporation

                            South Korea arrow
                            CAMX
                            Not Confirmed

                            Enzychem Lifesciences Corporation

                            South Korea arrow
                            CAMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mosedipimod

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Undisclosed

                            Sponsor : National Institutes of Health

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Enzychem Lifesciences Selected to Collaborate with NIAID CCRP on the CERF Program

                            Details : Enzychem's lead compound, EC-18, is an immunomodulator that rapidly resolves inflammation and restores immune homeostasis by accelerating the intracellular trafficking of pattern recognition receptor-bound pathogenic invaders or endogenous danger signals...

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            April 20, 2021

                            Lead Product(s) : Mosedipimod

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Undisclosed

                            Sponsor : National Institutes of Health

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Erdal

                            Germany arrow
                            CAMX
                            Not Confirmed

                            Erdal

                            Germany arrow
                            CAMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Undisclosed

                            Sponsor : ActoPharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Erdal Can Alkoclar to Renew Antiviral License for ActoPharma

                            Details : The biopharmaceutical formulation consisting of two flavanol glycoside analogues is designed to simultaneously reduce viral load, decrease platelet aggregation and modulate the cytokine ratios in order to effectively suppress cytokine storm.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            January 26, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Undisclosed

                            Sponsor : ActoPharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Eton Pharmaceuticals

                            U.S.A arrow
                            CAMX
                            Not Confirmed

                            Eton Pharmaceuticals

                            U.S.A arrow
                            CAMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ethanol

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Eton Pharmaceuticals Submits New Drug Application to the FDA for Orphan Drug Dehydrated Alcohol Injection (DS-...

                            Details : Eton Pharmaceuticals has submitted a new drug application (NDA) for dehydrated alcohol injection, previously known as the company’s DS-100 product candidate, to the U.S. Food & Drug Administration (FDA) for the treatment of methanol poisoning.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 27, 2020

                            Lead Product(s) : Ethanol

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth